52 Week Range
As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
GSK Gets Positive CHMP Opinion For Intravenous Benlysta In Children With Lupus Aged 5 & Above
Microsoft - Charles Noski And Helmut Panke To Retire From Board - SEC Filing
FDA Panel Says Benefits Of GlaxoSmithKline's OTC Nicotine Oral Spray Outweigh Risks
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Biotechnology & Drugs
G S K House, 980 Great West Road
Jonathan Richard Symonds
Independent Non-Executive Chairman of the Board
Emma N. Walmsley
Chief Executive Officer, Executive Director
Iain James Mackay
Chief Financial Officer, Executive Director
Roger G. Connor
President - Vaccines
Chief Executive Officer - GSK Consumer Healthcare
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Microsoft Corp said on Thursday it has nominated GlaxoSmithKline Plc Chief Executive Officer Emma Walmsley to its board of directors.
An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc's over-the-counter nicotine oral spray that aims to help smokers quit their addiction.
An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc's over-the-counter nicotine oral spray that aims to help smokers quit their nicotine addiction.
* Fasenra gets U.S. FDA orphan drug status (Adds details on Breztri data)
GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business.
GlaxoSmithKline's experimental HIV injection is as effective when given every other month as monthly, according to a study, a convenience that could help the British drugmaker in its battle against a rival drug from Gilead Sciences.GSK's two-drug injection was as effective...
British drugmaker GlaxoSmithKline Plc said on Thursday its long-lasting two-drug regimen to treat HIV met the main goal of a late-stage study.
AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer.
British drugmaker GlaxoSmithKline <GSK.L> is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.
British drugmaker GlaxoSmithKline is handing over all its development work on three potential vaccines against the deadly Ebola and Marburg viruses despite an ongoing Ebola outbreak in Democratic Republic of Congo.
GlaxoSmithKline <GSK.L> beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit this year than originally anticipated.
GlaxoSmithKline Plc on Wednesday forecast a smaller than previously estimated fall in full-year profit after the British drugmaker beat profit consensus for the second quarter due to demand for its fast-growing Shingles vaccine.
GlaxoSmithKline Plc on Wednesday forecast a smaller-than estimated fall in full-year profit after the British drugmaker beat profit consensus for the second quarter due to demand for its fast-growing Shingles vaccine.
GlaxoSmithKline <GSK.L> has appointed HSBC's <HSBA.L> Jonathan Symonds to succeed Philip Hampton as non-executive chairman, ending a six month search as the drugmaker prepares to split its businesses into two.
Drugmaker GlaxoSmithKline Plc on Wednesday named HSBC's Jonathan Symonds as non-executive chairman to replace Philip Hampton. (Reporting by Pushkala Aripaka in Bengaluru; editing by Jason Neely)
Switzerland has agreed to extradite a Chinese researcher to the United States where prosecutors have charged him with helping his scientist sister steal secrets allegedly worth $550 million from British drugmaker GlaxoSmithKline.
(This July 10 story corrects to show patients switched from Gilead's Descovy, not Gilead's Vemlidy, in fifth paragraph)
GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage study, the drugmaker said on Wednesday.
GlaxoSmithKline Plc's cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said on Monday.
GlaxoSmithKline said on Monday a late-stage study testing Zejula as a maintenance therapy in patients with first-line ovarian cancer showed positive headline results.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.